EA021886B1 - Выделенная фракция мастиковой смолы - Google Patents

Выделенная фракция мастиковой смолы Download PDF

Info

Publication number
EA021886B1
EA021886B1 EA201190168A EA201190168A EA021886B1 EA 021886 B1 EA021886 B1 EA 021886B1 EA 201190168 A EA201190168 A EA 201190168A EA 201190168 A EA201190168 A EA 201190168A EA 021886 B1 EA021886 B1 EA 021886B1
Authority
EA
Eurasian Patent Office
Prior art keywords
myrcene
fraction
poly
polymer
isolated
Prior art date
Application number
EA201190168A
Other languages
English (en)
Russian (ru)
Other versions
EA201190168A1 (ru
Inventor
Задик Хазан
Original Assignee
Редженера Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редженера Фарма Лтд. filed Critical Редженера Фарма Лтд.
Publication of EA201190168A1 publication Critical patent/EA201190168A1/ru
Publication of EA021886B1 publication Critical patent/EA021886B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
EA201190168A 2009-03-04 2010-03-04 Выделенная фракция мастиковой смолы EA021886B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15721509P 2009-03-04 2009-03-04
PCT/IL2010/000183 WO2010100650A2 (en) 2009-03-04 2010-03-04 Therapeutic uses of mastic gum fractions

Publications (2)

Publication Number Publication Date
EA201190168A1 EA201190168A1 (ru) 2013-01-30
EA021886B1 true EA021886B1 (ru) 2015-09-30

Family

ID=42224206

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201492259A EA201492259A1 (ru) 2009-03-04 2010-03-04 Терапевтические применения фракций мастиковой смолы
EA201190168A EA021886B1 (ru) 2009-03-04 2010-03-04 Выделенная фракция мастиковой смолы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201492259A EA201492259A1 (ru) 2009-03-04 2010-03-04 Терапевтические применения фракций мастиковой смолы

Country Status (12)

Country Link
US (4) US8956601B2 (zh)
EP (1) EP2403505B8 (zh)
CN (2) CN106619700A (zh)
AU (1) AU2010220056B2 (zh)
BR (1) BRPI1013223A2 (zh)
CA (2) CA2974805C (zh)
DK (1) DK2403505T3 (zh)
EA (2) EA201492259A1 (zh)
ES (1) ES2617875T3 (zh)
HU (1) HUE032032T2 (zh)
PL (1) PL2403505T3 (zh)
WO (1) WO2010100650A2 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene
ES2562807T3 (es) * 2009-10-28 2016-03-08 Regenera Pharma Ltd. Monoterpenos poliméricos para tratar la función neurológica alterada
EP2613777B1 (en) 2010-09-07 2019-05-01 Regenera Pharma Ltd. Compositions comprising acidic extracts of mastic gum
WO2013186766A1 (en) * 2012-06-11 2013-12-19 Regenera Pharma Ltd. Extracts and therapeutic uses thereof
MX369696B (es) * 2013-10-11 2019-11-19 ABSORBezz LLC Método y composición para mejorar la salud animal.
KR101645721B1 (ko) * 2014-12-30 2016-08-05 대전대학교 산학협력단 위장질환 예방 및 치료용 유향 함유 조성물
IL237621A0 (en) * 2015-03-08 2015-06-30 Regenera Pharma Ltd Use of isolated fractions of the gum goddess to treat optic neuropathy
KR20180053406A (ko) 2015-09-24 2018-05-21 레제네라 파마 리미티드 트리테르페노이드 포함 조성물
JP6879573B2 (ja) * 2015-09-24 2021-06-02 レジネラ ファーマ リミテッド トリテルペノイドを含む組成物
WO2018047175A1 (en) 2016-09-08 2018-03-15 Regenera Pharma Ltd. Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
EA201990561A1 (ru) * 2016-09-08 2019-09-30 Регенера Фарма Лтд. Композиции, содержащие кислотные экстракты мастиковой камеди, и их применение для лечения оптической нейропатии
KR102300227B1 (ko) * 2021-04-08 2021-09-09 주식회사 프롬바이오 매스틱 검 수용액을 포함하는 탈모 방지 및 발모 촉진용 화장료 조성물
KR102328824B1 (ko) * 2021-07-12 2021-11-23 주식회사 프롬바이오 수용화 매스틱 검과 감태나무 추출물을 이용한 발모 촉진 또는 탈모 억제용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012454A1 (en) * 1988-06-14 1989-12-28 Omer Osama L M A medicinal herb mixture for the treatment of depression
WO2003092712A1 (en) * 2002-05-01 2003-11-13 Lavipharm S.A. Use of mastic and its components for the control of microbial infections
WO2006053249A2 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374957A (en) 1981-10-29 1983-02-22 Michigan Molecular Institute Triblock polymers of a monovinyl aromatic compound and myrcene
US4564718A (en) 1984-08-14 1986-01-14 The University Of Manchester Institute Of Science And Technology Functionally terminated polymers from terpene monomers and their applications
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS63179908A (ja) 1987-01-22 1988-07-23 Japan Synthetic Rubber Co Ltd ミルセン重合体およびその製造方法
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US5506406A (en) 1993-05-17 1996-04-09 Atomic Energy Corporation Of South Africa Ltd. Method and apparatus for determining the concentration of a heavy element in a rock face
US5759569A (en) 1995-01-10 1998-06-02 The Procter & Gamble Company Biodegradable articles made from certain trans-polymers and blends thereof with other biodegradable components
US5714007A (en) 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
GR950100243A (el) 1995-06-28 1997-02-28 �. �����- �. ����� �.�.�. Χρησιμοποιηση της φυσικης μαστιχας χιου η του εξαγομενου εξ'αυτης φυσικου μαστιχελαιου η συνθετικων παραγωγων του για την παρασεκυη οδοντοκρεμας, οδοντικου διαλυματος, αποσμητικου στοματος, αντιηλιακων, προιοντων μαλλιων, καθως και καλλυντικων προιοντων.
JPH10130254A (ja) 1996-11-01 1998-05-19 Jumoku Seiri Kinousei Butsushitsu Gijutsu Kenkyu Kumiai ジヒドロクマリン系化合物およびエストロゲン作用剤
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GR1003541B (el) 1999-05-11 2001-03-07 Αντιμικροβιακη και αντιμυκητιακη δραση του εξαγομενου απο τα κλαδια, φυλλα και καρπο της μαστιχας χιου -pistacia lentiscus var chia-, μαστιχελαιου, για χρηση σε καλλυντικες, φαρμακευτικες και παραφαρμακευτικεσς εφαρμογες καθως και στην παραγωγη οδοντοτσι
GR1003550B (el) 1999-09-22 2001-03-13 Σταθερο παρασκευασμα ισοεξυλοναφθαζαρινων με πεντα- και τετρα-κυκλικα τριτερπενια, συστατικα φυτικων ελαιορητινων και κομμεων
US6623728B2 (en) 2000-06-30 2003-09-23 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Cosmetic skin care compositions and containing gum mastic
US7056491B2 (en) 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
GR1003868B (el) 2001-02-06 2002-04-19 Lavipharm S.A. Αξιολογηση των επουλωτικων, αντιοξειδωτικων και κυτταροστατικων ιδιοτητων της μαστιχας και των συστατικων της, και οι εφαρμογες τους
CA2437578A1 (en) 2001-02-13 2002-08-22 Rivka Cohen Carotenoid-loaded liposomes
US6534548B1 (en) 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
JP2004083443A (ja) 2002-08-23 2004-03-18 Hideji Watanabe マスティックを用いた歯周病予防・治療用組成物及び歯周病予防・治療方法
US7423100B2 (en) 2002-12-20 2008-09-09 Exxonmobil Chemical Patents Inc. Polymerization processes
AU2003297458A1 (en) 2002-12-20 2004-07-22 Exxonmobil Chemical Patents Inc. Polymerization processes
US20050074509A1 (en) 2003-10-02 2005-04-07 Data Medica Padova S.P.A. Cancer treatment using natural plant products or essential oils extracted from some pistacia species or components
WO2005053812A1 (en) 2003-12-08 2005-06-16 Xylon Biotechnologies Ltd. Plant materials extraction method
WO2005085306A1 (ja) 2004-03-04 2005-09-15 Riken アイソタクチック３，４−イソプレン系重合体
WO2005112967A2 (en) 2004-05-19 2005-12-01 Balfour Marketing Corp. Anticancer activity of chios mastic gum
US20070292445A1 (en) 2004-07-06 2007-12-20 Transpharma Medical Ltd. Delivery system for transdermal immunization
AU2005274765B2 (en) 2004-07-23 2012-08-30 Arjil Pharmaceuticals Llc Anti-hypersensitive inflammation and anti-allergy activities of Zingiber zerumbet (L.) Smith
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
US20070148187A1 (en) * 2005-12-27 2007-06-28 Intact Enterprises, Inc. Mastic gum composition for use as a dietary supplement in humans and animals
CN100478335C (zh) * 2006-11-30 2009-04-15 上海力智生化科技有限公司 一种环氧月桂烯的制备方法
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012454A1 (en) * 1988-06-14 1989-12-28 Omer Osama L M A medicinal herb mixture for the treatment of depression
WO2003092712A1 (en) * 2002-05-01 2003-11-13 Lavipharm S.A. Use of mastic and its components for the control of microbial infections
WO2006053249A2 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Khan M.B. ET AL.: "Prevention of cognitive impairments and neurodegeneration by Khamira Abresham Hakim Arshad Wala", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE LNKD-DOI: 10.1016/J.JEP.2006.04.012, vol. 108, no. 1, 3 November 2006 (2006-11-03), pages 68-73, XP025085972, ISSN: 0378-8741 [retrieved on 2006-11-03], figures; tab. 3, * abstract *
MAGIATIS PROKOPIOS ET AL.: "EVALUATION OF THE WOUND HEALING, ANTIOXIDANT AND CYTOSTATIC PROPERTIES OF MASTIC AND ITS ELEMENT AND RELATIVE APPLICATIONS" EPODOC, 19 April 2002 (2002-04-19), XP002597055, the whole document *
MANSOURI S.M.T. ET AL.: "The effect of Pistacia vera L. gum extract on oxidative damage during experimental cerebralischemia-reperfusion in rats", IRANIAN BIOMEDICAL JOURNAL, PASTEUR INSTITUTE OF IRAN, IRAN, vol. 9, no. 4, 1 October 2005 (2005-10-01), pages 181-185, XP009137543, ISSN: 1028-852X, * abstract *
VAN DEN BERG K.J. ET AL.: "Cis-1,4-poly-beta-myrcene; the Structure of the Polymeric Fraction of Mastic Resin (Pistacia lentiscus L.) Elucidated", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL LNKD-DOI: 10.1016/S0040-4039(98)00228-7, vol. 39, no. 17, 23 April 1998 (1998-04-23), pages 2645-2648, XP004112120, ISSN: 0040-4039, the whole document *
YOUSUF S. ET AL.: "Protective effect of Khamira Abresham Uood Mastagiwala against free radical induced damage in focal cerebral ischemia", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE LNKD-DOI:10.1016/J.JEP.2004.12.035, vol. 99, no. 2, 3 June 2005 (2005-06-03), pages 179-184, XP025270097, ISSN: 0378-8741, [retrieved on 2005-06-03], * abstract *

Also Published As

Publication number Publication date
AU2010220056A1 (en) 2011-10-13
US8956601B2 (en) 2015-02-17
EP2403505B8 (en) 2017-03-15
WO2010100650A2 (en) 2010-09-10
US20160287654A1 (en) 2016-10-06
CN106619700A (zh) 2017-05-10
CA2754564A1 (en) 2010-09-10
AU2010220056B2 (en) 2015-04-02
BRPI1013223A2 (pt) 2017-09-26
EP2403505A2 (en) 2012-01-11
CN102413833B (zh) 2017-02-08
US10251923B2 (en) 2019-04-09
EP2403505B1 (en) 2016-12-07
EA201492259A1 (ru) 2015-04-30
WO2010100650A3 (en) 2010-11-25
ES2617875T3 (es) 2017-06-20
PL2403505T3 (pl) 2017-06-30
CA2974805C (en) 2021-11-30
DK2403505T3 (en) 2017-03-06
CA2974805A1 (en) 2010-09-10
US20150110902A1 (en) 2015-04-23
US9364509B2 (en) 2016-06-14
US20120003175A1 (en) 2012-01-05
WO2010100650A4 (en) 2011-02-03
CA2754564C (en) 2017-09-12
EA201190168A1 (ru) 2013-01-30
HUE032032T2 (en) 2017-09-28
CN102413833A (zh) 2012-04-11
US20190192594A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
US10806763B2 (en) Compositions of polymeric myrcene
US10251923B2 (en) Therapeutic uses of mastic gum fractions
US10159680B2 (en) Compositions comprising acidic extracts of mastic gum
AU2015203595B2 (en) Therapeutic uses of mastic gum fractions
AU2015203604A1 (en) Insecticidal Composition and Method

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TJ TM